Hisham Abukamleh, MD
Internal Medicine · Apple Valley, CANPI 1144689647
Payments from drug & device makers
Across 212 payments — averaging $19.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$657
- AstraZeneca$631
- Novo Nordisk$476
- Lilly USA, LLC$448
- Johnson & Johnson$296
- Boehringer Ingelheim$192
- plus $1K from 24 others
What the payments were for
- Food & beverage$4,077100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 24 | $657 |
| AstraZeneca | 33 | $631 |
| Novo Nordisk | 36 | $476 |
| Lilly USA, LLC | 25 | $448 |
| Johnson & Johnson | 19 | $296 |
| Boehringer Ingelheim | 12 | $192 |
| Abbott | 4 | $174 |
| Bayer | 9 | $162 |
| GSK | 7 | $148 |
| Amgen | 5 | $97 |
| Boston Scientific | 1 | $88 |
| Dexcom, Inc. | 4 | $82 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| ANI Pharmaceuticals, Inc. | 3 | $67 |
| Exact Sciences | 3 | $62 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $59 |
| AbbVie | 2 | $40 |
| Mylan Specialty L.p. | 2 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Philips North America LLC | 2 | $32 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Esperion Therapeutics, Inc. | 1 | $24 |
| Corcept Therapeutics | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Phadia US Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Almatica Pharma LLC | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$4,077 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 182 | $188,064 |
| EliquisApixaban | 158 | $148,262 |
| JardianceEmpagliflozin | 88 | $78,065 |
| JanuviaSitagliptin Phosphate | 76 | $71,413 |
| FarxigaDapagliflozin Propanediol | 74 | $71,366 |
| XareltoRivaroxaban | 55 | $49,635 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $36,104 |
| TrulicityDulaglutide | 25 | $33,809 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 39 | $22,974 |
| MounjaroTirzepatide | 19 | $18,511 |
| SteglatroErtugliflozin Pidolate | 46 | $18,386 |
| LinzessLinaclotide | 26 | $18,150 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $16,661 |
| VemlidyTenofovir Alafenamide | 11 | $15,175 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $14,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $476 | $201,991197 claims |
| PfizerEliquis | $657 | $148,262158 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $631 | $94,03799 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $192 | $84,656101 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humulin 70-30, Humulin N | $448 | $57,77374 claims |
| Johnson & JohnsonXarelto, Invokana | $296 | $55,94066 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $148 | $41,79658 claims |
| AbbVieLinzess | $40 | $18,15026 claims |
| Sanofi-aventis U.S. LLCLantus | $28 | $4,00526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Apple Valley
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.